Merck KGaA (BMV:MRK1 N) - Stock Price, News & Analysis

MRK1 N Stock Overview

Operates as a science and technology company in Germany. More details

MRK1 N fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	2/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 38.4% below our estimate of its fair value

Earnings are forecast to grow 10.7% per year

Analysts in good agreement that stock price will rise by 32.1%

Risk Analysis

Shares are highly illiquid

Merck KGaA Competitors

Genomma Lab Internacional. de

BMV:LAB B

Mex$25.2b

GSK

LSE:GSK

UK£53.5b

Chugai Pharmaceutical

TSE:4519

JP¥10.6t

Zoetis

NYSE:ZTS

US$79.0b

Price History & Performance

Summary of all time highs, changes and price drops for Merck KGaA
Historical stock prices
Current Share Price	€3,299.85
52 Week High	€3,299.85
52 Week Low	€2,878.21
Beta	0.71
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-32.51%
5 Year Change	n/a
Change since IPO	-2.37%

Recent updates

Shareholder Returns

	MRK1 N	MX Pharmaceuticals	MX Market
7D	0%	-1.7%	-1.5%
1Y	n/a	-18.0%	-3.1%

Return vs Industry: Insufficient data to determine how MRK1 N performed against the MX Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how MRK1 N performed against the MX Market.

Price Volatility

Is MRK1 N's price volatile compared to industry and market?
MRK1 N volatility
MRK1 N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.2%
10% least volatile stocks in MX Market	2.6%

Stable Share Price: MRK1 N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine MRK1 N's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1668	62,255	Belen Garijo Lopez	www.merckgroup.com/en

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

Merck KGaA Fundamentals Summary

How do Merck KGaA's earnings and revenue compare to its market cap?
MRK1 N fundamental statistics
Market cap	Mex$1.30t
Earnings (TTM)	Mex$57.79b
Revenue (TTM)	Mex$449.36b

22.6x

P/E Ratio

2.9x

P/S Ratio

Is MRK1 N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRK1 N income statement (TTM)
Revenue	€20.96b
Cost of Revenue	€8.64b
Gross Profit	€12.33b
Other Expenses	€9.63b
Earnings	€2.70b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Mar 06, 2025

Earnings per share (EPS)	6.20
Gross Margin	58.80%
Net Profit Margin	12.86%
Debt/Equity Ratio	37.8%

How did MRK1 N perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

36%

Payout Ratio

MRK1 N Stock Overview

Rewards

Risk Analysis

Merck KGaA Competitors

BMV:LAB B

Mex$25.2b

LSE:GSK

UK£53.5b

TSE:4519

JP¥10.6t

NYSE:ZTS

US$79.0b

Price History & Performance

Recent News & Updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Full year 2023 earnings released: EPS: €6.49 (vs €7.65 in FY 2022)

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Upcoming dividend of €1.85 per share

Now 21% undervalued after recent price drop

Now 22% undervalued

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Merck Launches New, High-Purity Synthetic Cholesterol Product

First quarter 2021 earnings released

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Full year 2020 earnings released: EPS €4.57 (vs €2.97 in FY 2019)

Revenue beats expectations

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib

MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021

4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

Shareholder Returns

Price Volatility

About the Company

Merck KGaA Fundamentals Summary

22.6x

2.9x

Earnings & Revenue

Dividends

1.6%

36%